deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT01935947

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

A Randomized Phase II Trial of Cytotoxic Chemotherapy With or Without Epigenetic Priming in Patients With Advanced Non-Small Cell Lung Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Non-Small Cell Lung Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer
Interventions Azacitidine Docetaxel Entinostat Gemcitabine Hydrochloride Irinotecan Hydrochloride Laboratory Biomarker Analysis Pemetrexed Disodium
Updated 9 times since 2017 Last updated: Jun 29, 2018 Started: May 31, 2013 Primary completion: Apr 30, 2017 Completion: Apr 30, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Recurrent Non-Small Cell Lung Carcinoma trials with similar outcome

Browse all Recurrent Non-Small Cell Lung Carcinoma trials

Listed as NCT01935947, this PHASE2 trial focuses on Recurrent Non-Small Cell Lung Carcinoma and Stage IIIA Non-Small Cell Lung Cancer and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 9 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~May 2017 · 3 months · monthly snapshotActive Not Recruiting~May 2017 – ~Jun 2018 · 13 months · monthly snapshotTerminated~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshotTerminated~Aug 2018 – ~Jan 2021 · 29 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  5. Aug 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Jun 2018 — Aug 2018 [monthly]

    Terminated PHASE2

  2. May 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations